Genocea Biosciences, Inc.
(NASDAQ : GNCA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.74%306.720.0%$5256.57m
BNTXBioNTech SE 3.17%344.060.0%$1596.83m
NVAXNovavax, Inc. -0.92%160.4878.2%$831.00m
AMGNAmgen, Inc. 0.63%202.441.4%$596.39m
GILDGilead Sciences, Inc. -0.16%69.561.0%$505.86m
REGNRegeneron Pharmaceuticals, Inc. 0.18%635.162.7%$472.48m
VRTXVertex Pharmaceuticals, Inc. -0.31%203.811.9%$464.56m
LGVNLongeveron Inc. 11.78%20.120.0%$429.77m
ILMNIllumina, Inc. -2.85%347.283.3%$324.28m
SNSSSunesis Pharmaceuticals, Inc. -4.21%4.100.7%$286.61m
BIIBBiogen, Inc. -2.01%223.921.8%$276.52m
INCYIncyte Corp. -1.28%65.782.4%$150.25m
SGENSeagen Inc. -5.00%150.745.8%$149.09m
EXASEXACT Sciences Corp. -4.94%76.5918.0%$140.15m
OCGNOcugen, Inc. -8.72%5.760.0%$139.18m

Company Profile

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The firm uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.